# 20/20 GeneSystems

Biomarker Testing for Multi-Cancer Early Detection and Longevity

- Canonical URL: https://wefunder.com/2020.gene.systems
- Entity ID: wefunder:company:143261
- Last updated: 2026-06-17T05:02:46Z
- Generated at: 2026-06-17T22:41:11Z

## Quick facts
- 20/20 is a leader in the Multi-Cancer Early Detection (MCED) market, expected to reach $50B.
- VC investments: Wako (Fujifilm), PingAn, Calvert (Morgan Stanley), MD Venture Fund, Brevet, Keiretsu
- Secured $5M+ in research grants/contracts from National Cancer Institute (NCI) and others.
- Ranked #134 on 2023 Inc. 5000 list of the “Fastest Growing Companies in America” (#1 in Maryland).
- Utilize technology from Abbott Diagnostics and Roche Diagnostics for our MCED solutions.
- Sales volume from our cancer testing grew 2.2X from 2022 to 2023.
- Multiple issued or allowed patents in the U.S. and East Asia (available in Downloads section).
- Our team has 100+ years of combined biotech/life science experience. Board chair sold BioDx to Opko.

## Active fundraises
- wefunder:fundraise:97561: 4(a)(6) successful (USD)
- wefunder:fundraise:97562: 4(a)(6) successful (USD)

## Story
The survival rate for many types of cancer significantly improves when treatment is started early, following detection at early stages before the cancer has spread to distant organs. Unfortunately, screening is common for only a small number of tumor types (breast, colon, prostate, cervix) but not for many deadly cancers such as those of the lung, liver, pancreas, and ovaries. Since cancer does not discriminate by income or region, we believe that making tests affordable and accessible is as important as making them accurate.  Simply put, new and innovative cancer tests should be made affordable and available to everyone who is at risk for developing this dreaded disease.Leading global venture funds have invested in 20/20—now it's your opportunity to join them.In June 2021, the company Grail launched their Galleri test, a multi-cancer early detection (MCED) blood test based on circulating tumor DNA (ctDNA).  Three months later, Grail was acquired by Illumina for over $7 billion in cash and stock.   Another company, Thrive, was acquired by Exact Sciences in 2020 for $2.15B.   Since then, leading medical authorities, such as New York Times bestselling author of Outlive, Peter Attia, MD have embraced and encouraged this new screening paradigm.   Almost $100 million in Galleri tests were sold in 2023. Securities analyst Puneet Souda estimates the MCED market will eventually generate $50 billion in annual sales.Passage of this bill is a top 2024 priority for the American Cancer Society and many other disease advocacy organizations.   The National Institutes of Health, with support from the White House Cancer Moonshot, is investing more than $100 million to support multi-year clinical trials of MCEDs.  Significant momentum has been building for MCEDs since 2021, but there are several key problems with competing tests, nearly all of which rely on ctDNA.OneTest for Cancer is an MCED centered on measurements of the levels of antigens that tend to rise early in tumor development.  It is based on a testing approach that is near-universal throughout East Asia.  Each year, many adults in Japan, Korea, and China visit “Health Check-up” Centers where their nearly four-hour physical exam almost always includes an assessment of circulating tumor antigens. 20/20 has developed and validated AI powered algorithms utilizing real-world outcome data from tens of thousands of previously tested individuals.                          Using robotic analyzers with biomarker detection kits that are mass produced to meet demand in East Asia permits us to offer our tests at a fraction of the costs of ctDNA.  Furthermore, our test sensitivity for many earlier stage cancers is superior to that reported by our leading competitors. Additionally, proteins and other biomarkers in OneTest can be detected in fingerstick quantities of capillary blood permitting these tests to be accessed without the need for phlebotomists.    OneTest is a patented multi-cancer early detection (MCED) blood test that integrates well-established biomarkers with cutting edge Al technology. It is recommended for healthy, middle-aged adults who seek to lower their risks of facing late-stage, deadly cancers.  It is paid for by employers or the individuals who order the test, the same payment model common throughout East Asia and with our competitors in the U.S.  Earlier detection of cancers of the lung, pancreas, liver, and ovaries are among those that the test may be particularly useful, as these cancers are not commonly screened for in the U.S. The test can work with even a small quantity of blood using capillary collection techniques and is sent to our CLIA certified, CAP Accredited lab where it is run using sophisticated FDA approved automated analyzers from companies like Roche and Abbott Diagnostics, the same robotic instruments used in major hospital systems. Within about 3 business days, we issue a comprehensive lab report that includes biomarker values and their associated expected ranges provided by the manufacturer for each marker. These values are then plugged into our proprietary machine learning algorithms along with clinical factors such as age and gender to produce our innovative OneTest risk scores.  Our algorithms improve the accuracy of these tests compared to the biomarker values alone.Once the blood is tested and the OneTest risk scores are generated, a detailed report is uploaded onto our HIPAA compliant patient portal where consumers are able to review results.  Importantly, the portal enables the consumer to see graphics showing the changes in their marker values over time as they get tested over the years. These trends are very valuable clinically and an increase in marker values over time can be a sign of malignancy. Our mission is to make blood tests that aid in the early detection of cancer available to every adult through offering tests that are better, more affordable, and easier to access than anything else on the market.  We make these tests available to everyone so we can help people detect and treat cancers early, ultimately leading to better cancer outcomes and saving lives.  We accomplish this mission by using AI and real-world data to improve upon well established and widely used biomarkers like CEA, AFP, and PSA.  This allows us to keep the costs of running our tests low because our reagents are readily available and commonly used around the world.  The data from these tests can then easily be plugged into our state-of-the-art algorithms to improve their accuracy and provide personalized cancer risk assessments.All testing is performed in a tightly regulated CLIA licensed, CAP accredited, high complexity laboratory with an exemplary record of compliance.  Our lab personnel are very experienced running tests in a high throughput environment, and our state of the art laboratory testing instruments enable us to turn results around rapidly.We are committed to further research not only to improve our currently available cancer tests but to add new and innovative tests to our menu in the future. We will use the same spirit of innovation that drove us in the journey to OneTest Premium in order to continue to enhance our cancer offerings and soon launch new cutting edge tests including capillary blood collection techniques and tests that aid in healthy aging and longevity.  20/20 has 4 U.S. patents covering AI powered cancer blood tests with new patents soon to issue in Asia.  Furthermore, during the first half of 2024, we expect to close a major exclusive patent license and sponsored research agreement with one of the world’s largest cancer centers.  This will substantially expand our patent estate and give us access to unique and proprietary know-how, algorithms, archived blood specimen banks, and trade secrets.  Of note, the company founder and CEO, Jonathan Cohen, is a seasoned patent attorney very experienced in building and leveraging intellectual property in the diagnostics industry. Unlike most other available MCEDs, OneTest™ was developed from an entirely asymptomatic, real-world cohort of individuals, meaning that at the time of testing, patients were not known to have cancer and all identified cancers were detected in the post-test period.  Most developers use known cases of disease for test development which allows them to use smaller study cohorts. This latter approach may result in biomarker signatures that have greater ability to differentiate between cancer and non-cancer (greater sensitivity and specificity), but less overall utility, as they do not detect cancer as early. Our proprietary algorithms developed from our distinctive data sets are what make our tests truly unique.Clayton County is a customer that returns to us year after year testing approximately 300 firefighters on average because they recognize the value of OneTest not just for the health of their firefighters but for the cost benefits of our affordable tests and knowing that catching a cancer early can save a substantial amount of money in the long run.Our primary competition in the MCED arena is Grail and other companies seeking to deploy tests based on sequencing of circulating tumor DNA (ctDNA). There are three key disadvantages of ctDNA testing that our proteomic based (measurement of tumor antigens) approach overcomes:  We have a line of sight to profitability, but our priority for 2024-26 is growth.  Our major markets are employers and consumer initiated tests (CIT) although a growing number of physician groups are embracing our product, especially those focusing on preventative and lifestyle medicine.The MCED market, of which 20/20 is among the early entrants in the U.S., is huge and growing exponentially.  While not guaranteed, we estimate that these tests will yield nearly $30 billion in annual revenue worldwide by 2030.  (Other analysts project a market as large as $50 billion) *source A bill in Congress, endorsed by the American Cancer Society, and with more than half of all members as co-sponsors would accelerate Medicare coverages of MCEDs. 20/20 has engaged with the lead sponsor of that bill, as well as the Congressional Budget office, and believes that due to our price point, we may be positioned to be among the first to obtain national coverage.  President Biden’s “Cancer Moonshot” is prioritizing MCEDs and funding clinical trials at the National Cancer Institute (NCI). The NCI states that “The Cancer Moonshot is marshaling resources across the federal government to speed progress in cancer research and lead to improved cancer prevention.”  The aspect of the Cancer Moonshot program that is specifically focused on MCEDs is the NCI Vanguard Study on Multi-Cancer Detection.  This shows a commitment from the government to increase funding and effort into the cancer space and recognizes MCEDs as a crucial part in the fight against cancer going forward.  This trend of federal funding is trickling down into the states as well, as bills to provide firefighters funding for cancer screening are popping up across the country.  Maryland has already kicked off a multi-cancer screening grant program for firefighters and New Hampshire and Oklahoma are following suit.  20/20 has mainly focused our sales and marketing efforts in two major areas, employers and consumer initiated tests (CIT). Additionally, medical practices with a specialty in lifestyle and prevention are also becoming early adopters.  We have just scratched the surface in both of these  targets and their market size is continuing to grow.  Until now, fire departments have been our main focus on the employer side due to their increased cancer risk and our drive to serve  the first responder community.  However, we will begin to focus on employers in different sectors this year. Employee wellness is a growing aspect of companies, and we will tap into that market by becoming involved in large company HR / health and wellness plans.Our CIT market is another very exciting aspect of our business.  We have shown rapid CIT growth year over year, and we expect that trend to continue.  As more people learn about MCEDs through the buzz being created by the government to focus on them, people getting these tests and spreading the word, and our marketing efforts, we expect the market to continue to grow.  We anticipate our new capillary collected blood tests to grow out the D2C market even further. This will give people access to testing at the pharmacy counter and expand the availability of our test nationwide through adding more testing locations, thus adding  to the convenience of the sample collection aspect of this test.To review, the demand for MCEDs is increasing as this type of testing becomes more accepted as a routine part of an annual physical. The federal government is paving the way by pouring money into dedicated MCED research, and this is warming up both the employer and consumer initiated markets.  Every adult middle aged and above would likely benefit from using MCEDs like OneTest, and that opens the door for a very large segment of the population to order our tests.In 2024, there is intense interest in MCEDs with a bill in Congress to provide Medicare coverage for these tests having an unprecedented +300 co-sponsors (Republican and Democrat). Passage of this bill is a top priority of the American Cancer Society and is being championed on the editorial pages of The Wall Street Journal.  20/20 is uniquely positioned to benefit from this momentum with the only test priced low enough to be available to tens of millions of beneficiaries of Medicare and private insurance.2024 is expected to be a pivotal year for our company with a significant increase in sales, a large strategic financing investment, and a technology license and sponsored research agreement with one of the world’s largest cancer centers. We also expect to be the first and only provider of a multi-cancer test at retail pharmacies. A new longevity test is also planned for the second half of this year that will incorporate various biomarkers along with dietary and lifestyle recommendations based on peer reviewed scientific papers.  This community round, our fourth in as many years, is mainly a bridge to a much larger strategic investment we expect to close before the end of the first half of this year.  Proceeds from this round will mainly be used to advance sales and marketing with about 20% being used for research and development.   Current R&D involves AI algorithm improvements and validation of finger and upper arm capillary collection so that consumers can easily access our tests at their local pharmacy (and eventually at home).  20/20 was one of the first life sciences companies to succeed in a community rounds campaign. Today, life sciences and biotech companies are now among the most successful at this type of financing.  But most of these companies—especially those involved in drug development—are many years from getting a product to market.  20/20 is unique in that it combines the huge upside potential of biotech from a company already at a nearly $2 million revenue run rate with substantial growth expected by the end of 2024.   Lawmakers at the federal and state levels are, on the one hand, demanding lower costs for prescription drugs while advancing legislation to expedite coverage for multi-cancer tests.   Simply put, we offer a relatively lower risk but still very high return opportunity compared to our peers in the life sciences.  20/20 is also an opportunity to “do well while doing good” by generating future financial returns while potentially saving many lives along the way.  The fact that over 8,500 American firefighters are trusting their health to OneTest exemplifies our commitment to serving those who serve us all. Jama Network Journals

## FAQ
1. **What prior equity raises have you done? How have the price/valuation changed? Any splits along the way?**
   - The Company has raised $27.6M in equity since its inception in 2000. Approximately $16.5M has been raised over the past 10 years through crowdfunding and the pre-money valuations/pricing have increased as follows: 2014 $15M/$3.07ps; 2016 $20.8M/$3.26ps; 2017 $24M/$3.53ps; 2019 $37.8M/$4.40; $58M/$4.95ps; $70M/$5.34ps on this current round. There have been no splits or recapitalizations along the way.
2. **Good day there have been previous raises 2017 Microventures at $3.26 per share and 2020 StartEngine at $4.40 per share; what is $ per share for this raise and why the changes in funding platforms? Thanks Rob**
   - The $ per share pricing for this round is $5.34/share. Our last round of funding with StartEngine was not provided the same level of customer service that we were accustomed to in our previous rounds. Perhaps due to their rapid growth over the past few years we are not sure but where they would assign a campaign representative they shifted to a general e-mail for customer service support. We had heard good things about WeFunder and decided to try a different platform that would provide a camp...
3. **Hi Anne, I've been a shareholder since 2018 😊. I would like to invest again, but am a bit perplexed at the high minimum investment amount you’ve set. Why so high? Please consider the limitations placed on Non-accredited investors (read 'small investors') by the SEC . If I make...**
   - We are looking at this and will get back to you on whether we can lower our minimum.
4. **Are you able to share what your 2023 revenue was? Profitability?**
   - 2023 Revenue total was $1.4M and our net loss was $6.5M. We anticipate losses into 2025 as we invest in research and development activities and increase spending to expand our sales and marketing efforts to penetrate new and existing markets and launch new products.
5. **Being in healthcare, I love the concept of this company. Companies like this can transform healthcare in the future. My hesitation are your financials/being a tough financing environment right now. What is your path to sustain through your losses this year and next year and to...**
   - Adam, great question, we are actively raising money both in crowdfunding and through institutional investors, and we manage our cash flow closely. As you probably know from being in healthcare, many life science companies operate at a loss in the early years from the creation of the products to launching the products and many years after that; look at Grail who is our biggest competitor (they are still in the red due to heavy marketing & R&D). We will continue to operate lean with a f...

## Team
- Jonathan Cohen (CEO)
- Michael Lebowitz (Ph.D., Chief Scientific Officer)
- Jiming Zhou (Ph.D., Chief Operation Officer )
- John Compton (Ph.D., Board Chair)
- Michael A. Ross (M.D., Board Member)
- Anne Shiflett (Acting CFO)

## Recent posts
- Wefunder Discover Recording - 20/20 GeneSystems (2024-12-11T19:35:14Z)

## Q&A
- Q: I invested in 2018 through SeedInvest. What is the exit strategy for current investors? What are your plans for providing liquidity to existing shareholders - acquisition, IPO, etc?
  - A: We do not have a specific exit strategy at this time. The IPO market has been challenging the past few years, but we continue to watch it and prepare to be ready when the time is right. In the meantime, we are working hard to build value through expanded product offerings, enhanced technology, and growing both our consumer-initiated and commercial customer sectors to enable the best exit possible for our shareholders when the time is right.
- Q: When the Stock first came out if was trading at $50.00 a share by the time I got the email to get my shares transferred into my account it was below $2.00 Did only certain investors get to sell at the higher prices. I've invested in several of these over the years and this certainly was suspicious .
- Q: I invested in 2017 through SeedInvest now with startengine. What is the exit strategy for current investors? What are your plans for providing liquidity to existing shareholders once it goes to public?
- Q: How do I access your investor perk?
- Q: Where can I see my current investment?
- Q: Quanto está a cota da ação hoje? Qual marketcap da empresa?
- Q: what is my investment worth?
  - A: That can most accurately be determined after we go public, which we hope will take place in 2025.
- Q: I see from previous responses that investors who invested greater than 1,000 should have received an email regarding their complimentary test. I invested last year but have not received any such email. Who should I contact regarding their complimentary missing test.
  - A: investors@2020gene.com Ask Thatiana to get you the test to which you are entitled.
- Q: I invested in 2018 through SeedInvest. At the time the shares were issued at approximately $3.52 per share. Has there been any sort of stock splits, or has there really only been 52% appreciation in the company in the last 5+ years??
  - A: That is correct, the company has not had any stock splits since issuing the shares to you in 2018. With the growth in the MCED market, increased sales/revenue traction, and recent R&D developments into commercial products (OneTest Premium launched in October 2023) and soon rolling out a capillary collection for home and pharmacies as opposed to venipuncture have contributed to the increase in the Company's overall value since your initial investment. Through shareholder support and new investors, the Company has enhanced its offerings and overall value.
- Q: Perks... I am from the UK and invested previously, but never received my perk. What are your plans to offer previous and new investors perks if investing from the UK; is this possible and how?
  - A: Hi Sanjay, Shipping a blood specimen from the UK to our lab in the US offers some logistical difficulties, but we will reach out to you and see if we can figure something out.
- Q: I already invested $1000, how do I get the perk on 2020GeneSystems? I am InsideTracker user and would like to add cancer test to IT comprehensive test. Is 2020GeneSystems portal integrated with InsideTracker?
  - A: Hi Thomas, InsideTracker looks interesting. We are not integrated with their portal, but I will share their site with our team. We will be in touch soon to update you on how to access your perk. Thanks for your support!
  - A: Hi Thomas, Wanted to provide you a quick update on this. We will be sending out emails next week with instructions on accessing the perks. Thank you for your patience!
- Q: Are there any plans for expanding into new geographic regions or diversifying product offerings in the future?
  - A: Thanks for the question Ritesh. Currently, we are offering the OneTest algorithm via a software as a service (SAAS) model in parts of Asia, and we have ambitious plans to further expand our reach in these regions. We believe that there is potential for growth and adoption of our innovative cancer testing solutions in these markets. As you can see in the Mission section of our investment page, “We are committed to further research not only to improve our currently available cancer tests but to add new and innovative tests to our menu in the future. We will use the same spirit of innovation that drove us in the journey to OneTest Premium in order to continue to enhance our cancer offerings and soon launch new cutting edge tests including capillary blood collection techniques and tests that aid in healthy aging and longevity.”
- Q: How do you navigate regulatory challenges in the healthcare industry, especially regarding consumer-initiated testing? Are there any pending regulatory changes that could impact your operations or market access?
  - A: We are advised by highly qualified regulatory counsel, with special expertise in diagnostic testing. We work to ensure that that consumers who request our tests obtain an order from a physician, obtain prompt physician follow-up if their results are abnormal, and understand the strengths and limitations of our tests. In late April, the FDA issued a new rule mandating that laboratory developed tests (LDTs) would, for the first time, require pre-market approval from that agency beginning in late 2027. That rule is expected to be challenged in federal court and might be overruled by Congressional action. Fortunately, the rule provides that LDTs already on the market would not require FDA approval absent extraordinary circumstances. Thus, this regulation could offer some competitive advantages for OneTest and other LDTs that 20/20 is currently marketing since we one of only a small number of companies currently offering an MCED.
- Q: Can you provide insights into your marketing strategy to increase market penetration and brand awareness?
  - A: Our primary markets are employers (B2B) and individual consumers (B2C). For the former we attend trade shows and conferences and have a sales team that calls on those prospects. B2B leads also some from LinkedIn and other online platforms. (Fire Departments are one of our largest employer groups due to the high cancer incidences associated with this profession. Several states are now reimbursing our multi-cancer test for their firefighters.) For consumers, we market using common digital platforms such as Google and Facebook. We require a physician to order the test and to follow-up with those who have abnormal test results. Most consumers elect to use our telemedicine provider but some use their personal physician.
- Q: Good day there have been previous raises 2017 Microventures at $3.26 per share and 2020 StartEngine at $4.40 per share; what is $ per share for this raise and why the changes in funding platforms? Thanks Rob
  - A: The $ per share pricing for this round is $5.34/share. Our last round of funding with StartEngine was not provided the same level of customer service that we were accustomed to in our previous rounds. Perhaps due to their rapid growth over the past few years we are not sure but where they would assign a campaign representative they shifted to a general e-mail for customer service support. We had heard good things about WeFunder and decided to try a different platform that would provide a campaign representative throughout the entire campaign not just set up.